# Doxorubicin

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/doxorubicin
Canonical HTML page: https://getbiobrief.com/entity/doxorubicin

## Recent coverage (1 stories)

### Osteosarcoma's decades-old doxorubicin standard faces a 2.5-year-old
2026-09-13 21:31:16 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Mileah's treatment — doxorubicin-based chemotherapy followed by rotationplasty — reflects an osteosarcoma standard of care that has barely changed in decades, highlighting a rare pediatric tumor with high unmet need.
Full story: https://getbiobrief.com/story/osteosarcoma-doxorubicin-unmet-need-pediatric

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.